Nanohale AG (FYB) | WebDisclosure

Basculer en Français

8300	Companies
115014	Keywords
55394	Articles
62493	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/01/2024 at 17:06, 1 month 19 days ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH releases an update on Formycon AG, with analyst Simon Scholes reiterating a BUY rating and raising the price target from EUR 80 to EUR 82. The approval of the biosimilar FYB202 in the EU and US contributes to the positive outlook on Formycon's market share prospects

Investment Recommendation Formycon AG First Berlin Equity Research GmbH FYB202 Approval Biosimilar Market
BRIEF

published on 09/30/2024 at 07:35, 1 month 21 days ago

Formycon et Fresenius Kabi reçoivent l'approbation de la FDA pour le biosimilaire Otulfi

Approbation De La FDA Formycon Fresenius Kabi Biosimilaire Otulfi
BRIEF

published on 09/30/2024 at 07:35, 1 month 21 days ago

Formycon and Fresenius Kabi Receive FDA Approval for Biosimilar Otulfi

FDA Approval Biosimilar Formycon Fresenius Kabi Otulfi
PRESS RELEASE

published on 09/30/2024 at 07:30, 1 month 21 days ago

Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Formycon and Fresenius Kabi receive FDA approval for FYB202/OtulfiTM (ustekinumab-aauz) to treat several conditions including Crohn’s disease and psoriasis, expanding biosimilar market presence

FDA Approval Biosimilar Formycon Fresenius Kabi Ustekinumab
BRIEF

published on 09/27/2024 at 22:01, 1 month 23 days ago

FDA Grants Approval for Stelara® Biosimilar FYB202/OtulfiTM

FDA Approval Pharmaceutical Formycon AG Biosimilar Stelara®
BRIEF

published on 09/27/2024 at 22:01, 1 month 23 days ago

La FDA approuve le biosimilaire Stelara® FYB202/OtulfiTM

Formycon AG Approbation De La FDA Pharmaceutique Biosimilaire Stelara®
PRESS RELEASE

published on 09/27/2024 at 21:56, 1 month 23 days ago

EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
FDA grants approval for Stelara Biosimilar FYB202/Otulfi (ustekinumab-aauz) by Formycon AG. Approval based on comprehensive data evaluation. Contact: Sabrina Mueller, Formycon AG

FDA Approval Formycon AG FYB202 Stelara Biosimilar Sabrina Mueller
BRIEF

published on 09/27/2024 at 09:05, 1 month 24 days ago

European Commission Approves Formycon and Fresenius Kabi's Biosimilar FYB202/Otulfi®

European Commission Formycon Fresenius Kabi FYB202 Ustekinumab
BRIEF

published on 09/27/2024 at 09:05, 1 month 24 days ago

La Commission européenne approuve le biosimilaire FYB202/Otulfi® de Formycon et Fresenius Kabi

Formycon Fresenius Kabi FYB202 Ustekinumab Commission Européenne
PRESS RELEASE

published on 09/27/2024 at 09:00, 1 month 24 days ago

Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Formycon and Fresenius Kabi secure European Commission approval for FYB202/Otulfi® (ustekinumab) to treat inflammatory diseases, expanding biosimilar portfolio

Biosimilar Formycon Fresenius Kabi Ustekinumab European Commission Approval

Accesswire

Published on 11/21/2024 at 15:30, 38 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:05, 1 hour 3 minutes ago

"The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 1 hour 8 minutes ago

2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 1 hour 8 minutes ago

Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 1 hour 8 minutes ago

BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 15:41, 26 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 44 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 45 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 46 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 15:20, 47 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc

Les Echos

Published on 11/21/2024 at 06:58, 9 hours 10 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 10 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 9 hours 10 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 20 hours 1 minute ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 48 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE